Treating Myelofibrosis in 2021: What Are the Efficacy Data for Ruxolitinib? Is Allo-HCT a Good Curative Option in Advanced Disease? | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

8th Eurasian Hematology Oncology Summit

Treating Myelofibrosis in 2021: What Are the Efficacy Data for Ruxolitinib? Is Allo-HCT a Good Curative Option in Advanced Disease?

By 8th Eurasian Hematology Oncology Summit FEATURING Haifa Kathrin Al-Ali

By 8th Eurasian Hematology Oncology Summit FEATURING Haifa Kathrin Al-Ali

179 views

June 11, 2021

Comments 0

Login to view comments. Click here to Login